Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma

NCT00901147 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Peripheral T-cell Lymphoma (Not Otherwise Specified)
Angioimmunoblastic T-cell Lymphoma
Extranodal NK/T-cell Lymphoma Nasal Type
Enteropathy- Type T-cell Lymphoma
Hepatosplenic T-cell Lymphoma
Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)
Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant

Interventions

DRUG: panobinostat and bortezomib

Sponsor

Singapore General Hospital